Selection and description of cancer clinical trials participants--science or happenstance? (Q34810785)

4 August 2017

0 references

1 reference

title

Selection and description of cancer clinical trials participants--science or happenstance? (English)

1 reference

4 August 2017

G Marie Swanson

1

1 reference

PubMed ID

12209677

4 August 2017

John C Bailar

series ordinal

2

1 reference

PubMed ID

12209677

4 August 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

4 August 2017

10

1 reference

inferred from page(s)

published in

Cancer

1 reference

4 August 2017

95

1 reference

4 August 2017

5

1 reference

4 August 2017

950-959

1 reference

Recruiting minorities into clinical trials: toward a participant-friendly system

4 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

Current issues surrounding women and minorities in drug trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

Historical background of clinical trials involving women and minorities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

Evaluating minority recruitment into clinical studies: how good are the data?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

Effects of individualized breast cancer risk counseling: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

The Women's Health Trial Feasibility Study in Minority Populations: design and baseline descriptions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

The Working Well Trial: baseline dietary and smoking behaviors of employees and related worksite characteristics. The Working Well Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

Subgroup analysis and other (mis)uses of baseline data in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

Issues in comparisons between meta-analyses and large trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

Inclusion of women in clinical trials--policies for population subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

7 January 2021

Women and the development of drugs: why can't a woman be more like a man?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

7 January 2021

Politically correct clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

7 January 2021

Women in clinical trials of new drugs. A change in Food and Drug Administration policy. The Working Group on Women in Clinical Trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

7 January 2021

Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993--the perspective of NIH clinical trialists

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

7 January 2021

Prognosis among African-American women and white women with lymph node negative breast carcinoma: findings from two randomized clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

7 January 2021

Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

7 January 2021

Final results of the Maryland WIC 5-A-Day Promotion Program

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

7 January 2021

A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

7 January 2021

Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid-

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

7 January 2021

Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

7 January 2021

Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

7 January 2021

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

7 January 2021

Gender differences in smoking cessation after 3 years in the Lung Health Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

7 January 2021

National guidelines, clinical trials, and quality of evidence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

7 January 2021

The promise and problems of meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10785

7 January 2021

Identifiers

DOI

10.1002/CNCR.10785

1 reference

4 August 2017

1 reference

PubMed ID

12209677